Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haoxi Health Technology Limited filings document foreign private issuer reporting for a China-based online marketing solutions provider with Class A ordinary shares listed on Nasdaq. Form 6-K reports furnish interim financial statements, management discussion and analysis, material-event disclosures and exhibits tied to the company’s operating results, liquidity and shareholder equity.
The company’s regulatory record also covers auditor changes, board composition, shareholder meeting notices and proxy materials, material agreements, shelf registration and at-the-market offering documents, private placement agreements, termination of financing arrangements and capital-structure disclosures involving ordinary shares and related securities.
Haoxi Health Technology Limited held an extraordinary general meeting where shareholders approved several corporate changes, including a share capital increase and a share consolidation. The meeting had participation from 819,094 of 2,222,501 Class A ordinary shares and all 317,897 Class B ordinary shares. Class A shares carried one vote each and Class B shares carried thirty votes each, and all proposals received strong support based on the reported vote counts.
Haoxi Health Technology Limited is calling a 2026 extraordinary general meeting on June 2, 2026 to seek major changes to its share structure and governing documents. Shareholders will vote on a massive increase in authorized capital, new constitutional documents, potential future share consolidations and an adjournment authority.
The board proposes lifting authorized capital from US$384.25 million to US$35,200,000,000,000, creating up to 100 trillion Class A and 10 trillion Class B shares at US$0.32 par value each. It also seeks approval to adopt amended memorandum and articles, including changing the quorum to one-third of outstanding voting power, and to authorize one or more share consolidations between 1‑for‑2 and 1‑for‑8,000 over two years to help maintain Nasdaq listing requirements.
Haoxi Health Technology Ltd CEO and Chairman Fan Zhen, a ten percent owner, reported an open-market purchase of 40,000,000 Class B Ordinary Shares at $0.018 per share. After this transaction, Fan Zhen directly holds 40,690,800 Class B Ordinary Shares.
Haoxi Health Technology Limited entered into a Securities Purchase Agreement with its CEO, Zhen Fan, to sell 40,000,000 Class B ordinary shares at US$0.018 per share. This provides US$720,000 in gross proceeds, which the company plans to use for working capital and general corporate purposes. The price is about 101.12% of the Nasdaq closing price of its Class A shares on May 18, 2026, and the issuance relies on private placement exemptions under the U.S. Securities Act. The deal is a related-party transaction reviewed and approved by the audit committee, which deemed the terms fair and negotiated on an arm’s-length basis. After closing, Zhen Fan will beneficially own 40,690,800 Class B shares, representing about 83.83% of the company’s aggregate voting power.
Haoxi Health Technology Limited closed a registered direct offering of 9,000,000 Class A ordinary shares at $0.25 per share and 16,999,998 pre-funded warrants, generating gross proceeds of $6,455,799.51 before fees. Each pre-funded warrant was sold at $0.2474 and is immediately exercisable at $0.0026 per share, with each warrant exercisable for 10.355 Class A shares, or up to 176,034,979 shares in total.
The offering closed on May 12, 2026. As of that date, the company had issued 146,445,353 Class A shares in this transaction, including 137,445,353 shares from the exercise of 13,273,332 pre-funded warrants, and had 205,198,381 Class A shares and 690,800 Class B shares outstanding. Net proceeds are intended for working capital and general corporate purposes. The company agreed to 30-day restrictions on new equity issuance and variable rate transactions, while directors, officers and >5% shareholders agreed to 90-day lock-ups.
Haoxi Health Technology Ltd. is offering 9,000,000 Class A ordinary shares at $0.25 per share and 16,999,998 pre-funded warrants (exercisable into up to 176,034,979 Class A shares), for gross proceeds of up to $6,455,799.51. The Pre-Funded Warrants have a $0.0026 exercise price and are exercisable upon issuance. The placement agent is Univest Securities, LLC. Pro forma net proceeds, assuming full exercise, are approximately $5.93 million. The offering is subject to PRC filing requirements under the CSRC Overseas Listing Trial Measures; the company says it will file with the CSRC within three working days after completion. The prospectus highlights risks tied to PRC regulatory developments, data/security rules, and potential HFCA Act delisting triggers tied to PCAOB inspection access. Key reported 2025 results: revenue $32.80 million and net income $3,876,680. Shares outstanding prior to offering: 58,753,028 Class A and 690,800 Class B (as of May 11, 2026).
Haoxi Health Technology Limited reported strong revenue growth but a steep increase in losses for the six months ended December 31, 2025. Net revenue rose to $33.83 million from $23.95 million, as the company expanded its online marketing services for healthcare advertisers and exited loss-making overseas operations, which helped lift gross margin to 4.72% from 2.01%.
Despite higher sales and improved margins, Haoxi recorded a net loss of $6.88 million, sharply wider than the $0.23 million loss a year earlier. The main drivers were a $6.02 million allowance for credit losses on prepaid advertising and third-party loans, and a $0.90 million impairment on digital intangible assets.
Operating cash outflow was $2.27 million, and the company invested $4.50 million in a convertible bond, partly funded by equity. Haoxi raised $4.93 million net from financing, including follow-on share offerings and warrant-related share issuances, ending the period with $6.80 million in cash and $15.96 million in shareholders’ equity. Management believes current liquidity covers at least 12 months of needs but acknowledges continued negative operating cash flows as it scales.
Haoxi Health Technology Limited reported a change in its independent auditor. The audit committee dismissed Wei, Wei & Co., LLP as the company’s independent registered public accounting firm, effective April 3, 2026, and appointed HCL, PLLC as the new independent auditor, also effective April 3, 2026.
The company states that during the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period, the former auditor issued no adverse opinions or qualifications, had no disagreements on accounting or auditing matters, and no “reportable event” occurred. The company also confirms it did not consult HCL, PLLC on accounting or audit issues before the engagement.
Haoxi Health Technology Ltd director and Chief Operating Officer Xu Lei LX reported their holdings in the company. The Form 3 filing shows direct ownership of 214,400 Class A ordinary shares of Haoxi Health Technology Ltd, reflecting the executive’s initial reported equity position in the issuer.
Haoxi Health Technology Ltd director Su Changmao has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The filing does not report any stock transactions, share holdings, or derivative positions in the provided data for this reporting person.